Prellis using bioprinted lymph nodes to develop antibodies to SARS-CoV-2 AM Industry
The antibodies created using synthetic lymph nodes bioprinted by Prellis could also act as a prophylactic treatment option for the virus. This, the company explains, would effectively externalize a human’s immune system development. The antibody therapy could also be used to treat COVID-19 patients to minimize the severity of symptoms.